IGF-1 LR3
IGF-1 LR3 is a synthetic analog of insulin-like growth factor-1 engineered with enhanced potency and prolonged half-life for research and therapeutic applications in muscle growth, cellular proliferation, and tissue regeneration.
Brief glance
The primary outcome is Performance, but it's also used for Recovery & Repair, Anti-Aging, Metabolic. This compound is considered a Peptide. It may be compounded in 503A pharmacies where allowed. It is not listed under a DEA schedule.
Overview
IGF-1 LR3 is a synthetic, long-acting analog of insulin-like growth factor 1 (IGF-1), modified with a 13-amino acid extension that reduces binding to IGF-binding proteins, resulting in a prolonged half-life of 20-30 hours and approximately three times greater potency than native IGF-1. As a pharmaceutical active ingredient, it acts as an agonist at IGF-1 receptors to promote anabolic signaling pathways, including protein synthesis, cell proliferation, and glucose uptake, primarily in muscle and other tissues. It is investigated for clinical roles in growth hormone deficiency, muscle wasting conditions such as those associated with HIV/AIDS, and metabolic optimization, though it lacks FDA approval for most therapeutic uses.
IGF-1 LR3 is a synthetic analog of insulin-like growth factor 1 (IGF-1), modified with an arginine substitution at position 3 and an extended N-terminal sequence to reduce binding to insulin-like growth factor-binding proteins. This structural alteration enhances its potency as an IGF-1 receptor agonist, approximately threefold greater than native IGF-1, while extending its half-life to 20-30 hours for improved metabolic stability. As a pharmaceutical active ingredient, it promotes anabolic processes including muscle hyperplasia, protein synthesis, and nutrient uptake in muscle tissue. Its clinical role centers on potential applications in growth optimization and tissue repair, though it lacks standard regulatory approval for therapeutic use and requires medical oversight due to risks like hypoglycemia.
Benefits
IGF-1 LR3 is indicated for growth hormone deficiency states and muscle-wasting conditions, including short stature in children, adult growth hormone deficiency, Turner syndrome, short bowel syndrome, and HIV/AIDS-related muscle wasting1. The therapeutic mechanism involves binding to insulin-like growth factor receptors on muscle and tissue cells, prolonging growth factor signaling through an extended half-life of 20–30 hours compared to native IGF-11,2. Clinical evidence supports its use for accelerating tissue repair and reducing recovery time in patients with impaired healing, as demonstrated in studies published in the Journal of Endocrinology and trials examining muscle strength preservation in atrophy disorders3. The peptide enhances protein synthesis and nitrogen retention in skeletal muscle while simultaneously promoting fat mobilization through improved insulin sensitivity and nutrient partitioning, creating a metabolic environment that preserves lean mass during catabolic states1,4. Additional therapeutic applications include supporting bone density in osteoporosis-prone populations and improving endothelial function for cardiovascular health, particularly in hormone-deficient patients who show inadequate response to conventional growth hormone replacement5.
Side effects
Common side effects of IGF-1 LR3 include hypoglycemia manifesting as dizziness, sweating, shakiness, fatigue, and brain fog, particularly due to its prolonged circulation and insulin-mimicking effects on glucose uptake, alongside headaches, nausea, muscle and joint pain, water retention, and injection site reactions4,6,7,8. Long-term or high-dose use raises risks of insulin resistance, receptor desensitization, organ enlargement such as heart growth, acromegaly-like symptoms including bone thickening and soft tissue expansion, and potential promotion of cancer cell growth through accelerated cellular proliferation2,4,6,7,9. Safety considerations emphasize dose-dependent effects that can be mitigated by proper carbohydrate intake, glucose monitoring, short cycles of 4-6 weeks, and avoiding use in those with diabetes, prediabetes, or cancer history, with vigilant screening for systemic impacts2,4,6,10. Regular blood sugar management and medical supervision are essential to minimize hypoglycemia and long-term complications like impaired insulin sensitivity6,7,9.
Mechanisms of action
IGF-1 LR3 binds to IGF-1 receptors on the surface of muscle cells, triggering a conformational change that initiates two primary intracellular signaling cascades: the PI3K/Akt/mTOR pathway and the MAPK/ERK pathway11. Through the PI3K/Akt branch, the peptide promotes protein synthesis, suppresses cell apoptosis, and facilitates glucose uptake into muscle tissue, thereby supporting muscle hypertrophy and metabolic efficiency11,12. The MAPK/ERK pathway drives cell cycle progression and differentiation through transcription factor activation11. A critical structural distinction from native IGF-1—the substitution of arginine at position 3 and addition of 13 amino acids at the N-terminus—results in dramatically reduced binding affinity for insulin-like growth factor-binding proteins (IGFBPs), approximately 1,000-fold lower than native IGF-17,11. This reduced IGFBP interaction allows a substantially greater fraction of administered peptide to remain bioavailable and engage IGF-1 receptors, effectively increasing potency and extending the compound's half-life to approximately 20–30 hours, roughly twice that of native IGF-17,13.